Volastra, a biotech startup researching treatments for metastatic cancer, raised $44 million in an expansion of its seed round. The company also formed a partnership with Microsoft to develop algorithms to detect and predict potential metastases.
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.